- Topic
82k Popularity
242 Popularity
115k Popularity
109 Popularity
31k Popularity
- Pin
- 🚀 ETH jumped to $4,600 this morning, up 8.69% in 24h!
Just shy of the $4,891 ATH—think it breaks through?
📍 Follow Gate_Square, vote and drop your reason.
🎁 4 winners split $100 Futures Voucher! - 📢 Exclusive on Gate Square — #PROVE Creative Contest# is Now Live!
CandyDrop × Succinct (PROVE) — Trade to share 200,000 PROVE 👉 https://www.gate.com/announcements/article/46469
Futures Lucky Draw Challenge: Guaranteed 1 PROVE Airdrop per User 👉 https://www.gate.com/announcements/article/46491
🎁 Endless creativity · Rewards keep coming — Post to share 300 PROVE!
📅 Event PeriodAugust 12, 2025, 04:00 – August 17, 2025, 16:00 UTC
📌 How to Participate
1.Publish original content on Gate Square related to PROVE or the above activities (minimum 100 words; any format: analysis, tutorial, creativ - 💙 Gate Square #Gate Blue Challenge# 💙
Show your limitless creativity with Gate Blue!
📅 Event Period
August 11 – 20, 2025
🎯 How to Participate
1. Post your original creation (image / video / hand-drawn art / digital work, etc.) on Gate Square, incorporating Gate’s brand blue or the Gate logo.
2. Include the hashtag #Gate Blue Challenge# in your post title or content.
3. Add a short blessing or message for Gate in your content (e.g., “Wishing Gate Exchange continued success — may the blue shine forever!”).
4. Submissions must be original and comply with community guidelines. Plagiarism or re - 🎉 The #CandyDrop Futures Challenge# is live — join now to share a 6 BTC prize pool!
📢 Post your futures trading experience on Gate Square with the event hashtag — $25 × 20 rewards are waiting!
🎁 $500 in futures trial vouchers up for grabs — 20 standout posts will win!
📅 Event Period: August 1, 2025, 15:00 – August 15, 2025, 19:00 (UTC+8)
👉 Event Link: https://www.gate.com/candy-drop/detail/BTC-98
Dare to trade. Dare to win.
$NVO expands legal battle over compounded weight loss drugs Aug. 05, 2025 $HIMS
Novo Nordisk (NVO) on Tuesday announced 14 new lawsuits filed against vendors selling cheaper compounded versions of its blockbuster medication semaglutide, marketed as Wegovy for patients with obesity.
The announcement came a day after the digital weight-loss company Noom launched low-dose copies of semaglutide at a sharp discount to the branded product in a market dominated by its telehealth rival Hims & Hers Health (HIMS).
“The defendants named in these lawsuits employ tactics that deceive patients into believing compounded products have been reviewed and approved by the FDA or have equivalent safety or effectiveness as Novo Nordisk's approved semaglutide medicines,” NVO said.
Compounded pharmacies have been barred from selling copies of semaglutide after the FDA officially declared that the shortage for the popular GLP-1 injectable ended early this year.
“No one should have to gamble with their health by using knockoff drugs made with ingredients that lack oversight and safety standards," Novo’s U.S. head of operations, Dave Moore, said, adding, "We urge regulators to enforce laws designed to protect public health."
The latest lawsuits bring the total number of cases filed by the company in federal courts to 132 across 40 states.